Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1180-

  Mori, Masahiro ^a   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THIAZOLE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, LYSOSPHINGOLIPID; THIAZOLES;

EID: 84896416471     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-307538     Document Type: Editorial

References (7)

1. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
2. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
3. Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014;85:1198-208.
4. Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67.
5. Zipp F, Vollmer TL, Selmaj KW, et al. Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, phase II trial (DreaMS), Lyon, France. http://registration.akm.ch/einsicht.php?XNABSTRACT-ID=156130&XNSPRACHE-ID=2&XNKONGRESS-ID=171&XNMASKEN-ID=900
6. Murakami A, Takasugi H, Ohnuma S, et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 2010;77:704-13.
7. Bigaud M, Guerini D, Billich A, et al. Second generation S1P pathway modulators: research strategies and clinical developments. Biochim Biophys Acta 2013. (in press).